Browse News
Filter News
Found 11 articles
-
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial
7/29/2021
Daewoong Pharmaceutical announced its phase 2B clinical trial topline results for Foistar, which is being developed as a treatment for COVID-19.
-
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Apabetalone Treatment Prevents COVID-19 Infection of Human Lung CellsApabetalone Inhibits SARS-CoV-2 Infection at Levels Comparable to Approved Antiviral
3/15/2021
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of a new article titled: “Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro”, on the pre-print server, bioRxiv.
-
Sagent Pharmaceuticals Announces Start of NIAID-Sponsored Study Investigating COVID-19 Treatments in Outpatients
2/12/2021
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that Camostat mesilate (Camostat), is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial
-
Sagent Pharmaceuticals Launches Phase 2 Trial to Evaluate Camostat Mesilate for COVID-19 Treatment
11/11/2020
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of COVID-19 in high-risk outpatients and has begun enrolling patients
-
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic'
10/27/2020
- Influenza A (IVA) animal model confirmed 75% clinical symptom improvement compared to the control group - Broad antiviral efficacy results against SARS-CoV-2 and IVA were presented at the ISIRV-AVG conference
-
Fluvoxamine Data Unveiled as Promising Early Treatment in Patients with Mild COVID-19
10/6/2020
The COVID-19 Early Treatment Fund (CETF), which is administered by Rockefeller Philanthropy Advisors, a 501(c)(3) organization created to ensure the rapid and successful completion of outpatient clinical trials of existing drugs that lead to effective early treatments for COVID-19,
-
Harrington Discovery Institute Announces Award Recipients in its COVID-19 Rapid Response Initiative
6/11/2020
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, in collaboration with Morgan Stanley GIFT Cures, announced 12 award winners in the COVID-19 Rapid Response Initiative.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.